[go: up one dir, main page]

MX2018006531A - Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. - Google Patents

Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.

Info

Publication number
MX2018006531A
MX2018006531A MX2018006531A MX2018006531A MX2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A
Authority
MX
Mexico
Prior art keywords
treatment
agents
cell proliferation
diseases associated
unwanted cell
Prior art date
Application number
MX2018006531A
Other languages
English (en)
Inventor
SEOANE SUÁREZ Joan
Soto Simon Atenea
Sala Hojman Ada
Huber Ruano Isabel
CHIGANCAS Vanesa
Anido Folgueira Judit
Original Assignee
Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron filed Critical Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Publication of MX2018006531A publication Critical patent/MX2018006531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G01N33/575—
    • G01N33/5752—
    • G01N33/57535—
    • G01N33/57545—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer de ovario, pulmón o colorrectal, mediante el uso de agentes capaces de inhibir la expresión o capaces de bloquear la actividad del factor inhibidor de la leucemia (LIF). La invención también se refiere a métodos in vitro para diseñar una terapia personalizada para un paciente que padece un cáncer de ovario, pulmón o colorrectal y para seleccionar a un paciente que padece alguna de dichas enfermedades, para ser tratado con un agente capaz de inhibir la expresión o capaz de bloquear la actividad del LIF.
MX2018006531A 2015-11-27 2016-11-28 Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. MX2018006531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382590.6A EP3173483A1 (en) 2015-11-27 2015-11-27 Agents for the treatment of diseases associated with undesired cell proliferation
PCT/EP2016/079031 WO2017089614A1 (en) 2015-11-27 2016-11-28 Agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
MX2018006531A true MX2018006531A (es) 2019-01-10

Family

ID=54849575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006531A MX2018006531A (es) 2015-11-27 2016-11-28 Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.

Country Status (9)

Country Link
US (2) US20180344759A1 (es)
EP (2) EP3173483A1 (es)
JP (2) JP7069013B2 (es)
KR (1) KR20180100316A (es)
AU (2) AU2016359920B2 (es)
CA (1) CA3006168A1 (es)
IL (2) IL305473A (es)
MX (1) MX2018006531A (es)
WO (1) WO2017089614A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
DK3555132T3 (da) 2016-12-19 2024-02-05 Medimmune Ltd Antistoffer mod lif og anvendelser deraf
KR20210021287A (ko) * 2018-04-12 2021-02-25 메디뮨 리미티드 암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합
MA52021A (fr) * 2018-05-14 2021-03-24 Fundacio Privada Inst Catalana De Recerca I Estudis Avancats Anticorps anti-lif et leurs formes galéniques
AU2019291305B2 (en) * 2018-06-18 2024-03-21 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-LIF antibody treatment in individuals with cancer
AU2019419468B2 (en) * 2019-01-04 2025-10-02 The Regents Of The University Of California Compositions and methods for promoting angiogenesis in the eye
CA3156080A1 (en) 2019-09-29 2021-04-01 Jacobio Pharmaceuticals Co., Ltd. LIF SPECIFIC BINDING MOLECULE AND ITS USE
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP3049110A2 (en) * 2013-09-23 2016-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies

Also Published As

Publication number Publication date
IL259486A (en) 2018-07-31
IL259486B1 (en) 2023-10-01
CA3006168A1 (en) 2017-06-01
IL259486B2 (en) 2024-02-01
AU2016359920A1 (en) 2018-06-28
AU2023203443A1 (en) 2023-06-29
US20220323478A1 (en) 2022-10-13
JP7069013B2 (ja) 2022-05-17
JP7410211B2 (ja) 2024-01-09
JP2019502664A (ja) 2019-01-31
EP3173483A1 (en) 2017-05-31
EP3380614A1 (en) 2018-10-03
KR20180100316A (ko) 2018-09-10
US20180344759A1 (en) 2018-12-06
AU2016359920B2 (en) 2023-03-02
IL305473A (en) 2023-10-01
JP2022115958A (ja) 2022-08-09
WO2017089614A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
PH12020551923A1 (en) Methods and compositions for treating cancer
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
WO2018190719A3 (en) Anti-sirp alpha antibodies
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX375746B (es) Combinación de lenalidomida y constructo de polipéptido, y sus usos.
CL2016002798A1 (es) Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX387283B (es) Tratamiento del cancer con tg02.
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
ZA201904533B (en) Antibodies against lif and uses thereof
MX2017013360A (es) Métodos para tratar el cáncer.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?